Efficacy of esketamine after cesarean section for women with symptoms of prenatal depression: A randomized controlled trial.
Psychiatry research November 16, 2025 Xue-Song, Ying-Yan Xu, Hua-Ping Xiong et al. 2 citations
Perioperative esketamine reduces the incidence of postpartum depression in women with prenatal depression undergoing cesarean section. In a randomized trial, 18.8% of women receiving esketamine developed postpartum depression at 6 weeks, compared to 39.3% in the placebo group. Esketamine also lowered early postpartum anxiety, improved pain control with less opioid use, and increased sleep duration. Dizziness was more common with esketamine.